Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nutriband Inc WT
(NQ:
NTRBW
)
1.500
UNCHANGED
Streaming Delayed Price
Updated: 3:56 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nutriband Inc WT
< Previous
1
2
3
4
Next >
Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application
October 31, 2024
Via
ACCESSWIRE
Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica
October 17, 2024
Via
ACCESSWIRE
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on October 17
October 02, 2024
Via
ACCESSWIRE
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
September 24, 2024
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors
May 16, 2024
Via
ACCESSWIRE
Nutriband Inc. Announces $8.4M Private Placement
April 19, 2024
Via
ACCESSWIRE
Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st
January 29, 2024
Via
ACCESSWIRE
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
September 24, 2024
From
FN Media Group LLC
Via
GlobeNewswire
NUTRIBAND RECEIVES CHINA PATENT NOTICE OF ALLOWANCE FOR ITS AVERSA™ ABUSE DETERRENT TRANSDERMAL TECHNOLOGY
September 24, 2024
Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for a patent application covering its Nutriband AVERSA™ abuse deterrent transdermal technology Nutriband...
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology
September 24, 2024
Via
ACCESSWIRE
Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch
September 20, 2024
Via
ACCESSWIRE
Nutriband Inc. Authorizes $1M Share Buyback Program
September 16, 2024
Via
ACCESSWIRE
Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
September 04, 2024
Via
ACCESSWIRE
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25
July 19, 2024
Via
ACCESSWIRE
Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology
July 15, 2024
Via
ACCESSWIRE
Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl
June 20, 2024
Via
ACCESSWIRE
Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year
June 03, 2024
Via
ACCESSWIRE
Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission
April 24, 2024
Via
ACCESSWIRE
Nutriband Inc. Signs Exclusive Supplier Agreement with Major Sports Brand Licensee Fit for Life Group
April 23, 2024
Via
ACCESSWIRE
Nutriband Inc. Begins Manufacturing for Major Sports Brand Licensee Fit for Life Group, Whose Collection of Partnered Brands Include Reebok, Adidas and New Balance
April 01, 2024
Via
ACCESSWIRE
Nutriband Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch
March 27, 2024
Via
ACCESSWIRE
Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting
March 25, 2024
Via
ACCESSWIRE
Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting
March 04, 2024
Via
ACCESSWIRE
Nutriband CEO Publishes Letter to Shareholders
January 26, 2024
Via
ACCESSWIRE
Nutriband Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch
January 05, 2024
Via
ACCESSWIRE
Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling
November 28, 2023
Via
ACCESSWIRE
Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape
November 08, 2023
Via
ACCESSWIRE
Nutriband’s Aversa(TM) Buprenoprhine May Reach Peak Annual Sales 0f $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm
October 11, 2023
Via
ACCESSWIRE
Nutriband’s Innovative Patent Breaks New Ground in Transdermal Medications
September 20, 2023
Via
Get News
Topics
Intellectual Property
Exposures
Intellectual Property
Nutriband Unveils Groundbreaking Innovation in Transdermal Medications
September 20, 2023
ORLANDO, FL / September 20, 2023 (PlatoData via 500NewsWire) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a leading developer of transdermal pharmaceutical products, proudly announces the issuance...
Via
TheNewswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.